AU2013284338B2 - Compositions and methods for reducing frequency and/or severity of headache - Google Patents

Compositions and methods for reducing frequency and/or severity of headache Download PDF

Info

Publication number
AU2013284338B2
AU2013284338B2 AU2013284338A AU2013284338A AU2013284338B2 AU 2013284338 B2 AU2013284338 B2 AU 2013284338B2 AU 2013284338 A AU2013284338 A AU 2013284338A AU 2013284338 A AU2013284338 A AU 2013284338A AU 2013284338 B2 AU2013284338 B2 AU 2013284338B2
Authority
AU
Australia
Prior art keywords
adipose tissue
cells
stromal
subject
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013284338A
Other languages
English (en)
Other versions
AU2013284338A1 (en
Inventor
Pelin BRIGHT
Ralph BRIGHT
Bruce Hansen
Wayne Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell-Innovations Ip Pty Ltd
Original Assignee
Cell Innovations Ip Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902720A external-priority patent/AU2012902720A0/en
Application filed by Cell Innovations Ip Pty Ltd filed Critical Cell Innovations Ip Pty Ltd
Priority to AU2013284338A priority Critical patent/AU2013284338B2/en
Publication of AU2013284338A1 publication Critical patent/AU2013284338A1/en
Application granted granted Critical
Publication of AU2013284338B2 publication Critical patent/AU2013284338B2/en
Assigned to CELL-INNOVATIONS IP PTY LTD reassignment CELL-INNOVATIONS IP PTY LTD Request for Assignment Assignors: AMBERDALE ENTERPRISES PTY LTD, RUSTY PROPERTY HOLDINGS PTY LTD, TAVID PTY LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Vascular Medicine (AREA)
AU2013284338A 2012-06-26 2013-06-26 Compositions and methods for reducing frequency and/or severity of headache Active AU2013284338B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013284338A AU2013284338B2 (en) 2012-06-26 2013-06-26 Compositions and methods for reducing frequency and/or severity of headache

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012902720A AU2012902720A0 (en) 2012-06-26 Compositions and methods for reducing frequency and/or severity of headache
AU2012902720 2012-06-26
AU2013284338A AU2013284338B2 (en) 2012-06-26 2013-06-26 Compositions and methods for reducing frequency and/or severity of headache
PCT/AU2013/000684 WO2014000029A1 (en) 2012-06-26 2013-06-26 Compositions and methods for reducing frequency and/or severity of headache

Publications (2)

Publication Number Publication Date
AU2013284338A1 AU2013284338A1 (en) 2015-01-22
AU2013284338B2 true AU2013284338B2 (en) 2018-03-01

Family

ID=49781943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013284338A Active AU2013284338B2 (en) 2012-06-26 2013-06-26 Compositions and methods for reducing frequency and/or severity of headache

Country Status (9)

Country Link
US (1) US10206956B2 (enExample)
EP (1) EP2863927A4 (enExample)
JP (1) JP2015521630A (enExample)
KR (1) KR20150091037A (enExample)
CN (1) CN104902909A (enExample)
AU (1) AU2013284338B2 (enExample)
CA (1) CA2877022A1 (enExample)
NZ (1) NZ703345A (enExample)
WO (1) WO2014000029A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014262376A1 (en) * 2013-05-10 2015-11-26 Cell-Innovations Ip Pty Ltd Compositions and methods for the treatment of tinnitus
CN105555326B (zh) * 2013-07-01 2019-05-14 A·P·高伟尔 软组织植入物
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
JP6829225B2 (ja) * 2018-06-13 2021-02-10 株式会社 バイオミメティクスシンパシーズ モノアミン産生増加剤としての間葉系幹細胞を含む医薬組成物
CN110772535A (zh) * 2018-07-12 2020-02-11 南通大学 多系分化持续应激细胞在制备镇痛药物中的应用
JP6497827B1 (ja) * 2018-07-17 2019-04-10 株式会社 バイオミメティクスシンパシーズ エイコサノイド産生促進剤
US20210395693A1 (en) 2018-10-26 2021-12-23 Guy MARTI Method and apparatus for mesenchymal stem cells isolation and purification
JP2023549530A (ja) * 2020-11-13 2023-11-27 アドバンスト・セラピューティック・ラブ・インコーポレイテッド 脂肪組織に由来する間質血管細胞群を利用した治療方法及び組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039489A2 (en) * 2001-11-09 2003-05-15 Artecel Sciences, Inc. Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
WO2010021715A1 (en) * 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
WO2012083024A1 (en) * 2010-12-17 2012-06-21 Anthrogenesis Corporation Treatment of spinal cord injury and traumatic brain injury using placental stem cells
WO2012127320A1 (en) * 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366078C (en) 1999-03-10 2015-09-01 University Of Pittsburgh Of The Commonwealth System Of Higher Education Adipose-derived stem cells and lattices
AU2004263009B2 (en) 2003-08-07 2009-12-24 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
AU2004280616A1 (en) * 2003-10-08 2005-04-21 Vet-Stem Inc. Methods of preparing and using stem cell compositions and kits comprising the same
FR2901136B1 (fr) * 2006-05-18 2010-10-01 Centre Nat Rech Scient Utilisation de cellules derivees du tissu adipeux pour la preparation d'un medicament anti-tumoral
JP2010037292A (ja) 2008-08-06 2010-02-18 Univ Of Tokyo 脂肪由来幹細胞と塩基性線維芽細胞増殖因子を組み合わせた線維性病変の治療法
KR20110050521A (ko) 2008-08-20 2011-05-13 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
PT2379087E (pt) * 2008-12-19 2014-12-02 Depuy Synthes Products Llc Células derivadas do tecido do cordão umbilical para o tratamento da dor neuropática e espasticidade
AU2009100401A4 (en) * 2009-04-30 2009-06-04 Gl Holdings Inc Bv Method of extracting and activating adipose-derived stem cells
JP5917392B2 (ja) 2009-05-01 2016-05-11 ビミニ テクノロジーズ リミテッド ライアビリティ カンパニー 組織及び細胞富化グラフトを最適化するシステム、方法及び組成物
JP2011010581A (ja) 2009-06-30 2011-01-20 Kaneka Corp 幹細胞分離材、幹細胞分離フィルター、及び該分離材または該分離フィルターを用いた幹細胞分離方法、幹細胞回収方法
JP5905446B2 (ja) 2010-03-24 2016-04-20 ライフネット ヘルス Ｂｍｐ−４ペプチドおよび使用方法
JP2013528368A (ja) 2010-05-06 2013-07-11 ステム セル メディスン リミテッド 個の医療のための幹細胞バンク
CN103443272A (zh) * 2010-12-27 2013-12-11 智能细胞生物科学有限公司 从脂肪组织获得的源自超声空化的基质或间充质血管提取物和源自其的细胞以及其用途
PT2714059T (pt) * 2011-06-01 2019-02-04 Celularity Inc Tratamento da dor utilizando células estaminais da placenta
JP5598864B2 (ja) * 2011-12-05 2014-10-01 北海道公立大学法人 札幌医科大学 細胞増殖方法ならびに組織の修復および再生のための医薬

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039489A2 (en) * 2001-11-09 2003-05-15 Artecel Sciences, Inc. Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
WO2010021715A1 (en) * 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
WO2012083024A1 (en) * 2010-12-17 2012-06-21 Anthrogenesis Corporation Treatment of spinal cord injury and traumatic brain injury using placental stem cells
WO2012127320A1 (en) * 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OTERINO A, et al., 'Analysis of endothelial precursor cells in chronic migraine: A case control study,' Cephalagia, (6 November 2012), Vol 33(4), pp 236-244. *

Also Published As

Publication number Publication date
JP2015521630A (ja) 2015-07-30
CN104902909A (zh) 2015-09-09
NZ703345A (en) 2017-03-31
US10206956B2 (en) 2019-02-19
EP2863927A4 (en) 2015-12-02
WO2014000029A1 (en) 2014-01-03
US20150174172A1 (en) 2015-06-25
AU2013284338A1 (en) 2015-01-22
KR20150091037A (ko) 2015-08-07
EP2863927A1 (en) 2015-04-29
CA2877022A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
AU2013284338B2 (en) Compositions and methods for reducing frequency and/or severity of headache
US11236324B2 (en) Isolation of stem cells from adipose tissue by ultrasonic cavitation, and methods of use
EP2745840B1 (en) Composition including stem cell-derived microvesicles for use in promoting neurogenesis
Menkes et al. Subcutaneous injections of nanofat adipose-derived stem cell grafting in facial rejuvenation
JP6622189B2 (ja) 疼痛及び／又は線維症の調節において脂肪組織由来細胞を使用する方法
US20160120909A1 (en) Compositions And Methods For The Treatment Of Tinnitus
JP6362588B2 (ja) 毛髪再生用の細胞製剤
JP7591564B2 (ja) 変形性関節症を治療するための治療用アポトーシス細胞
RU2360965C1 (ru) СПОСОБ УВЕЛИЧЕНИЯ КОЛИЧЕСТВА ГЕМОПОЭТИЧЕСКИХ НЕДИФФЕРЕНЦИРОВАННЫХ СТВОЛОВЫХ КЛЕТОК ПАЦИЕНТА ex vivo
US20240010967A1 (en) Apparatus and method for isolating stem cells
CN108324992A (zh) 软骨修复用组合物及关节软骨的修复方法
US20160051701A1 (en) Improved methods for osteoarthritis therapy
US20240091269A1 (en) Treatment of bipolar disorder using mesenchymal stem cells and modification of mesenchymal stem cells
Park et al. Transplantation of rat adipose-derived stem cells (ASCs) to improve the survival of autologous aspirated fat grafts
RU2741769C2 (ru) Биомедицинский клеточный продукт, способ его получения и применения
US20200038451A1 (en) Stem cells as an individualized maternal therapy for prevention of prematurity
KR20240136869A (ko) 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법
Dolderer et al. Fundamentals of Fat Transplantation
JP2017079660A (ja) 細胞分離フィルターを用いた細胞濃縮液の製造方法
Tissiani et al. Effects of different liposuction techniques on the isolation of mesenchymal stem cells
Alexander Use of microcannula closed syringe system for safe and effective lipoaspiration and small volume autologous fat grafting
Saito-Reis THE TETRASPANIN CD82 REGULATES HEMATOPOIETIC STEM CELL FITNESS AND BONE MARROW RETENTION
WO2018017341A1 (en) Methods and compositions for rejuvenation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CELL-INNOVATIONS IP PTY LTD

Free format text: FORMER OWNER(S): AMBERDALE ENTERPRISES PTY LTD; RUSTY PROPERTY HOLDINGS PTY LTD; TAVID PTY LTD